Physician profile
Susannah C Cooper
NPI 1790846038
$7,538.45
in general payments reported to CMS, 2019-2025
53 companies · $527 in 2025
The $527 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.70 · 2021: $156 · 2022: $1,077 · 2023: $2,976 · 2024: $2,788 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,479 · Long Term Medical Supply Or Device Loan: $781 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,479.33 |
| Long Term Medical Supply Or Device Loan | $781.23 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,196.15 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $780.16 | 2022-2025 | Enhertu, Lynparza, Imfinzi |
| Pfizer INC. | $422.22 | 2019-2025 | |
| Amgen INC. | $372.29 | 2022-2025 | Imdelltra (Amg757), Blincyto, Kyprolis |
| Seagen INC. | $323.08 | 2022-2023 | Tukysa, Adcetris |
| Genentech USA, INC. | $305.54 | 2022-2024 | Lunsumio, Polivy, Alecensa |
| Regeneron Healthcare Solutions, INC. | $298.90 | 2022-2024 | Libtayo |
| Merck Sharp & Dohme LLC | $223.91 | 2022-2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $211.81 | 2023-2024 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $206.97 | 2022-2024 | |
| Incyte Corporation | $206.27 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Rigel Pharmaceuticals, INC. | $184.74 | 2021-2024 | Rezlidhia, Tavalisse |
| Pharmacosmos Therapeutics INC. | $167.54 | 2023-2024 | Monoferric |
| Abbvie INC. | $165.29 | 2022-2025 | Venclexta |
| Celgene Corporation | $164.11 | 2022-2024 | Reblozyl |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $142.39 | 2023-2024 | Trodelvy |
| Sumitomo Pharma America, INC. | $125.76 | 2023-2024 | Orgovyx |
| Daiichi Sankyo INC. | $112.72 | 2022-2024 | Enhertu |
| Stemline Therapeutics INC. | $107.30 | 2023-2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $103.14 | 2023-2024 | Alunbrig, Ninlaro, Iclusig |
| Astellas Pharma US INC | $101.97 | 2023-2024 | Xtandi, Padcev |
| Blueprint Medicines Corporation | $101.93 | 2023-2024 | Ayvakit |
| Jazz Pharmaceuticals INC. | $95.18 | 2022-2023 | Zepzelca |
| Pharmaessentia USA Corporation | $92.45 | 2022-2024 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $90.14 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $87.72 | 2022-2024 | Onivyde, Tazverik |
| Lilly USA, LLC | $84.16 | 2022-2024 | Jaypirca, Verzenio |
| Alexion Pharmaceuticals, INC. | $81.27 | 2022-2023 | Ultomiris |
| Genmab U.S., INC. | $73.12 | 2022-2024 | Epkinly |
| Puma Biotechnology, INC. | $69.82 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $67.22 | 2022-2023 | Opdivo |
| Glaxosmithkline, LLC. | $65.29 | 2023-2024 | Ojjaara |
| Sobi, INC | $61.73 | 2023-2024 | |
| Emd Serono, INC. | $58.53 | 2022-2023 | Bavencio |
| Kite Pharma, INC. | $55.97 | 2023-2024 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.12 | 2023 | Gilotrif |
| Morphosys, US INC. | $45.27 | 2022-2023 | Monjuvi |
| Beigene USA, INC. | $44.97 | 2022-2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $44.86 | 2023-2024 | Fotivda |
| Sun Pharmaceutical Industries INC. | $36.44 | 2023-2024 | Odomzo, Yonsa |
| Progenics Pharmaceuticals, INC. | $29.87 | 2023 | Pylarify |
| Tersera Therapeutics LLC | $29.18 | 2023 | Zoladex |
| Alnylam Pharmaceuticals INC. | $28.52 | 2023 | Givlaari |
| Mylan Institutional INC. | $27.15 | 2023 | Fulphila, Ogivri |
| Exelixis INC. | $27.05 | 2024 | Cabometyx |
| Cti Biopharma Corp. | $24.84 | 2023 | Vonjo |
| G1 Therapeutics, INC. | $24.79 | 2022 | |
| Myovant Sciences INC. | $23.92 | 2022 | |
| Sirtex Medical INC | $22.52 | 2024 | Sir-Spheres Microspheres |
| Karyopharm Therapeutics INC. | $21.67 | 2024 | Xpovio |
| Adaptive Biotechnologies Corporation | $18.05 | 2024 | Clonoseq |
| Taiho Oncology, INC. | $16.93 | 2023 | |
| Verity Pharmaceuticals INC. | $14.51 | 2023 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susannah Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.